Ameriprise Financial Inc. decreased its position in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 5.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 4,806,866 shares of the company's stock after selling 275,101 shares during the period. Ameriprise Financial Inc. owned about 1.26% of GoodRx worth $22,352,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. PDT Partners LLC acquired a new position in GoodRx in the 4th quarter valued at about $119,000. Northern Trust Corp increased its position in shares of GoodRx by 13.5% in the fourth quarter. Northern Trust Corp now owns 421,810 shares of the company's stock worth $1,961,000 after acquiring an additional 50,256 shares in the last quarter. Oxford Asset Management LLP purchased a new stake in shares of GoodRx in the fourth quarter worth about $75,000. Two Sigma Securities LLC purchased a new stake in shares of GoodRx during the fourth quarter valued at approximately $100,000. Finally, Price T Rowe Associates Inc. MD increased its stake in GoodRx by 28.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 255,192 shares of the company's stock worth $1,188,000 after buying an additional 56,522 shares during the period. 63.77% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of analysts have recently weighed in on GDRX shares. The Goldman Sachs Group decreased their price target on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Wells Fargo & Company decreased their target price on GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Truist Financial decreased their target price on GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a report on Thursday, April 10th. Finally, UBS Group reduced their target price on GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a report on Tuesday, May 13th. Five analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, GoodRx presently has a consensus rating of "Moderate Buy" and an average price target of $6.55.
View Our Latest Analysis on GoodRx
GoodRx Stock Performance
NASDAQ:GDRX traded down $0.03 during trading hours on Tuesday, reaching $3.93. The company had a trading volume of 72,839 shares, compared to its average volume of 1,473,331. GoodRx Holdings, Inc. has a 52 week low of $3.67 and a 52 week high of $9.26. The firm has a market cap of $1.40 billion, a price-to-earnings ratio of -130.83, a PEG ratio of 2.46 and a beta of 1.24. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The firm's 50 day moving average price is $4.43 and its 200-day moving average price is $4.63.
GoodRx (NASDAQ:GDRX - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. GoodRx had a positive return on equity of 5.35% and a negative net margin of 2.05%. The company had revenue of $202.97 million for the quarter, compared to the consensus estimate of $202.25 million. During the same period in the previous year, the business earned $0.08 earnings per share. The firm's revenue for the quarter was up 2.6% on a year-over-year basis. On average, analysts forecast that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.
About GoodRx
(
Free Report)
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Read More
Before you consider GoodRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.
While GoodRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
